Fred Hutchinson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fred Hutchinson Cancer Center sits in the top decile of US sponsors by registered trial count (#76 of 15,742 sponsors by registered trial count).
Fred Hutchinson Cancer Center: 483 sponsored US clinical trials, 57 recruiting.
Fred Hutchinson Cancer Center sponsors 483 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 327 completed. 27 of these trials are in Phase 3-4 (later-stage) and 304 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 10 trials.
Top-decile sponsor footprint
Fred Hutchinson Cancer Center ranks in the top decile of sponsors by registered trial count (#76 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
327 of 391 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
483 total, page 3 of 10
A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults
NCT05897242
Avatar-Led Digital Therapeutic for Aiding Smoking Cessation in Sexual and Gender Minority Young Adults
NCT05847673
A Video Intervention to Decrease Patient Fear of Colonoscopy After a Positive Fecal Immunochemical Test
NCT05458986
Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
NCT05592223
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
NCT04593277
A Multilevel Approach for Improvement in Screening of Colorectal Cancer in Rural Communities, The Screen to Save Trial
NCT05291988
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
NCT04083170
A Tailored Screening and Smoking Cessation Program for the LGBTQ Community of Seattle
NCT05304390
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
NCT04893018
mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation
NCT04525222
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
NCT04965597
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
NCT05135650
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
NCT04359784
Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
NCT04809766
Red and Processed Meat Effects on the Metabolome and Microbiome
NCT05274906
Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study
NCT04870515
eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors
NCT04081298
Educational Intervention for the Promotion of Knowledge and Preventive Health Behaviors Related to Personal Air Pollution Exposure, The Air Study
NCT04922697
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease
NCT04526288
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
NCT04639245
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis
NCT04706507
Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV
NCT04682301
Website Smoking Cessation Intervention for the Promotion of Smoking Cessation in Low-Income Veterans
NCT04502524
Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE Study
NCT04660331
Financial Navigation Intervention in Improving Financial and Clinical Outcomes in Patients With Newly Diagnosed Gastric or Gastroesophageal Junction Adenocarcinoma
NCT03986502
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
NCT04496219
Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer
NCT04211766
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning
NCT04889144
Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization
NCT04208724
Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant
NCT03125070
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
NCT04902144
Vaccine Responsiveness After CAR-T Cell Therapy
NCT04410900
Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers
NCT04194918
Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors
NCT04200482
Glasdegib for Chronic Graft-Versus-Host Disease
NCT04111497
Effects of Alternative Healthy Eating Index-Based Diet on Inflammatory Markers and Breast Density in Healthy Participants
NCT04062955
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
NCT03670069
Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
NCT04188912
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
NCT04060849
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
NCT03870750
Yeego! Healthy Eating & Gardening School-Based Randomized Controlled Trial
NCT03778021
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
NCT03747484
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
NCT03781778
Acute Exercise Intervention in Breast Cancer Survivors
NCT03779867
Reducing Insulin, Growth Hormones, and Tumors
NCT03785808
Resistance Training Program and Cardiovascular Exercise in Increasing Muscle Mass in Adolescent and Young Adult Stem Cell Transplant Survivors
NCT03672981
A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort
NCT03731637
Pilot Trial of the First Conversational Agent for Smoking Cessation (QuitBot)
NCT03585231
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm
NCT03531918
SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart
NCT03574012
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 144 |
| Phase 2 | 160 |
| Phase 3 | 25 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Fred Hutchinson Cancer Center pipeline
57 recruiting of 483 indexed (12% open); 327 completed (68%).
Phase mix: 27 late (III/IV) vs 304 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fred Hutchinson Cancer Center: open-pipeline peers nationwide
Peers matched on 483 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Fred Hutchinson Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 483 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Cochlear · 12% recruiting · 34 trials
- Erchonia Corporation · 12% recruiting · 34 trials
- Hutchmed · 12% recruiting · 17 trials
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 12% recruiting · 17 trials
Related
What to do with this Fred Hutchinson Cancer Center page
483 registered trials is a research-attention snapshot, not an endorsement of Fred Hutchinson Cancer Center or any single study.
- 57 of Fred Hutchinson Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Fred Hutchinson Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Fred Hutchinson Cancer Center pipeline card: 483 registered trials from official public datasets.Report a data error.